Short answer
Journey Medical Corp (DERM) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $17M (up 16.4% year over year) with net income of −$2M.
Q3 2025 key financials · XBRL
- Revenue
- $17M
- +16.4% YoY · +13.4% QoQ
- Net income
- −$2M
- +3.1% YoY · +39.0% QoQ
- Operating margin
- -9.0%
- EPS (diluted)
- −$0.09
- +18.2% YoY · +43.8% QoQ
Source: XBRL data from the Journey Medical Corp (DERM) Q3 2025 10-Q on SEC EDGAR. USD.
Journey Medical Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $17.6M, up 21% YoY from $14.6M, including $4.9M Emrosi revenue
- Q3 operating loss $1.5M vs $2.9M YoY; net loss $2.3M vs $2.4M
- Best performer Emrosi $4.9M; weakest Foam franchise $1.3M, down 38% YoY
- Cash $24.9M vs $20.3M at December 31, 2024; nine-month operating cash use $6.2M
- Emrosi launch drove growth; Accutane faced competition, with $5.7M nine-month revenue decline
Risk Factors
- Newly added tariff risk triggered by recent U.S. trade-policy changes, with significant finished-product imports from India
- Most materially updated healthcare risk: May 12, 2025 most-favored-nation pricing order targeting Medicare and Medicaid reimbursement
- Regulatory risk: FDA staffing cuts in early 2025 potentially delaying approvals, submissions, and post-marketing requirements
- Operational risk: retaliatory tariffs and trade barriers potentially increasing sourcing costs and reducing product margins
- Financial risk: prolonged government shutdown potentially restricting public-market access and necessary capital
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Journey Medical Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.